ASTHMA
 

The University of Illinois at Chicago is a member of AsthmaNet, a nationwide clinical research network created by the National Heart Lung and Blood Institute. Nationwide, AsthmaNet includes 17 Sites that conduct clinical trials on asthma in both adults and children.

 
  • Best African American Response to Asthma Drugs (BARD)
    PI: Jerry Krishnan, MD, PhD
    The goal of this trial is to identify the most effective step-up therapy for people of African ancestry with asthma.
     
  •  
  • Determining Differences in Airway Inflammation Between African American and Caucasian Asthmatics (DABA)
    IRB# 2012-0155
    PI: Sharmilee Nyenhuis, MD
    This study investigates how airway inflammation in asthma differs with race.
     
  •  
  • Mast Cell, Macrophage and Eosinophil Interactions in Asthma
    IRB# 200-0838
    PI: Gye Young Park, MD MSc
    Co-Investigators: Steven J. Ackerman, PhD, H. Ari Jaffe, MD, Susan Corbridge, PhD, APN, Sharmilee Nyenhuis, MD
    This study characterizes the role of airway and blood inflammatory cells (mast cells, eosinophils and macrophages) in the pathobiology of allergic airway inflammation.
     
  •  
  • Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA)
    Sponsored by Milton S. Hershey Medical Center and NHLBI
    IRB# 2011-0624
    PI: Jerry Krishnan, MD, PhD
    This trial investigates whether taking vitamin D in addition to inhaled steroids may help with asthma attacks and symptoms.
     
    Interested? Call 1-855-I-WHEEZE (1-855-494-3393)
    More Info
 

Upcoming Asthma Studies

  • SIENA
    PI: Jerry Krishnan, MD, PhD
    Steroids in Eosinophil Negative Asthma
    The goal of this trial is to identify the most effective use of corticosteroids in asthma therapy for different populations of patients.
  •  
  • STAT
    PI: Jerry Krishnan, MD, PhD
    Severe Asthma Treatment Add-On Trial
    The goal of this trial is to identify how to best manage asthma in patients with severe, poorly controlled asthma.
  •  
 

CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
 

The University of Illinois at Chicago is the only site in Illinois that participates in the nationwide COPD Clinical Research Network (COPD CRN). The COPD CRN is a consortium of clinical research centers, and is funded by the National Heart Lung and Blood Institute.

 
  • Comparative Effectiveness of a COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD
    Sponsored by NHLBI
    IRB# 2012-0997
    PI: Min Joo, MD, MPH
    This randomized-control clinical trial investigates if diagnosis and guided therapy with the use of spirometry is related to better patient associated outcomes compared to usual care which may or may not include the use of spirometry.
  •  
  • The Long-term Oxygen Treatment Trial (LOTT)
    Sponsered by NHLBI
    IRB# 2011-0688
    PI: Min Joo, MD, MPH
    This clinical study investigates the effects of supplemental oxygen therapy in patients with chronic obstructive pulmonary disease (COPD).
     
    Interested? Call 1-855-I-WHEEZE (1-855-494-3393)
    More Info
     
  • Lung Volume Reduction Coil Treatment in Patients with Emphysema(RENEW)
    Sponsered by PneumRx, Inc.
    IRB# 2013-0012
    PI: Kevin Kovitz, MD, MBA
    PneumRx is conducting an FDA-approved study to evaluate the safety and effectiveness of a medical device for patients with emphysema: the RePneu®(say ‘RENEW’) Lung Volume Reduction Coil. Coils are placed in the airways of the lung and work by compressing diseased portions of the lung, helping small airways stay open, so that breathing becomes easier and healthier parts of the lung can function more effectively.
     
    More information available on Clinicaltrials.gov
     
  • SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
    Sponsored by NHLBI
    IRB# 2011-0706
    PI: Jerry Krishnan, MD, PhD
    This trial investigates whether use of Simvastatin, a medicine usually used to lower cholesterol, may decrease the number and seriousness of COPD flare-ups.
     
    Interested? Call 1-855-I-WHEEZE (1-855-494-3393)
    More Info

 

The University of Illinois at Chicago is one of 6 sites nationwide to participate in the COPD Outcomes-based Network for Clinical Effectiveness & Research Translation (CONCERT)
Recruitment is now complete for CONCERT studies. Please check again for updates on future studies.

 

LEARNING INNOVATIONS THROUGH COLLABORATION (LINC)
 

With leadership from three academic medical centers, LINC is an interprofessional consortium of healthcare professionals and researchers at 9 organizations with expertise in clinical research, biostatistics, hospital medicine, cardiology, pulmonary medicine, medication management, post-acute care, and community service. LINC investigators provide care to diverse patient populations with a focused interest in COPD and/or Heart Failure.

Our Missions

  1. Improve functional health status in patients with chronic obstructive pulmonary disease (COPD) and/or heart failure (HF) and for the frail elderly by using a new care delivery model with formally trained community health workers who serve as Healthcare Coordinators to deliver evidence-based care in patients’ homes resulting in decreased hospital admissions and emergency visits and lower overall health costs.
  2. Extend primary care into patient’s homes by integrating Healthcare Coordinators into primary care practices using embedded case managers for supervision and information technology to optimize communication especially at times of hospital discharge.
  3. Develop a model for workforce development, training and deployment by creating a standardized curriculum for training community health workers as Healthcare Coordinators (including modules for COPD, HF, medication management including reconciliation, physical activity promotion and falls prevention, and connection to social services).
  4. Build a collaborative of medical centers in Illinois that engages community and national resources and government-funded agencies to form a team that will allow the continuing improvement of this care model and application to other patient populations.
  5. Develop implementation and dissemination tools for primary care practice providers so that this model of care can be rapidly disseminated with high fidelity across practices in the U.S.
 

LINC Members

Northwestern University Feinberg School of Medicine  
University of Illinois Hospital & Health Sciences System
The University of Chicago Medicine
American College of Chest Physicians (ACCP)    
Respiratory Health Association of Metropolitan Chicago (RHAMC)
CJE SeniorLife
SimplyRehab
Erie Family Health Center
AgeOptions 

 

PULMONARY FIBROSIS
 
 
  • A Phase II Trial of Inhaled Carbon Monoxide for the Treatment of Idiopathic Pulmonary Fibrosis
    IRB# 2011-0454
    PI: Roberto Machado, MD
    Sponsored by NIH
    This multicenter clinical trial, lead by Harvard University, aims to study the effects of inhaled Carbon Monoxide on Idiopathic Pulmonary Fibrosis.
     
    Interested in participating? Call (312)355-1470
    Research Coordinator: (312)355-5934
    More information available on Clinicaltrails.gov
 

PULMONARY HYPERTENSION
 
 
  • Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
    IRB# 2010-0722
    PI: Roberto Machado, MD
    The purpose of this Clinical trial is to evaluate the effectiveness of Carbon Monoxide as a potential treatment for Pulmonary Arterial Hypertension.
     
  • Genomic and Biomarker Studies in Pulmonary Hypertension
    IRB# 2010-0977
    PI: Roberto Machado, MD
    A data base is being developed to study Pulmonary Hypertension biomarkers at different stages of the disease.
     
  • A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With TYVASO (Terprostinil) Inhalation Solution
    WIRB# 20101884
    IRB# 2011-0675
    PI: Roberto Machado, MD
    This Clinical trial is designed to study nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso in patients with Pulmonary Arterial Hypertension.
     
    More information available on Clinicaltrails.gov
  •  
  • Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program
    WIRB# 20102084
    IRB# 2011-0988
    PI: Roberto Machado, MD
    This trail focus on improving the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional classification.
     
    More information available on Clinicaltrails.gov
 

PULMONARY RESEARCH REGISTRY (PRR)
 

IRB# 2011-0625

The PRR is a registry of individuals (with or without a lung condition) who have indicated an interest in participating in pulmonary research studies. PRR participants may be contacted by researchers in the future to ask if they wish to participate in a UIC Institutional Review Board approved clinical trial.

Interested?
More Info

 


SICKLE CELL DISEASE
 
 
  • The Blood Lung Consortium
    IRB# 2012-0455
    PI: Roberto Machado, MD
    A multicenter study. This research is being done to better understand Asthma patterns in Sickle Cell Disease.
  •  
  • Cardiovascular Complications of Sickle Cell Disease
    IRB# 2010-0365
    PI: Roberto Machado, MD
    This research is being done to better understand the effects of the Sickle Cell Disease on the Cardiovascular system; patients with this disease are at higher risk for cardiovascular dysfunction and pulmonary hypertension.
  •  
  • Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia
    IRB# 2010-0360
    PI: Roberto Machado, MD
    Clinical trial in collaboration with Medical College of Wisconsin. The purpose of this research is to evaluate the effects of two drugs, hydroxyurea and regadenoson on blood flow in patients with Sickle Cell Disease.
     
    Interested in participating? Call (312)355-1470
    Research Coordinator: (312)355-5934
    More information available on Clinicaltrails.gov
  •  
  • Genomic and Biomarker Studies in Sickle Cell Disease
    IRB# 2010-1125
    Sponsored by NIH
    PI: Roberto Machado, MD
    The purpose of this study is to develop a database to study the relationship of biomarkers and the progression on Sickle Cell Disease at different disease stages.
 

SLEEP DISORDERS
 
 
  • Biobehavioral Effects of Disturbed Sleep (BEDS)
    PI: David W. Carley, PhD
    With support from the Office of the Director of the NHLBI, UIC has formed the BEDS Research Consortium; comprising faculty members from 12 departments and 5 colleges at UIC as well as senior collaborators from both Northwestern University and University of Chicago. This consortium is working to blend the languages, concepts, methods and models of many traditional disciplines, focusing them on research into the connections between poor sleep and impaired biobehavioral and social function in health and disease. We aim to truly transform the research paradigm and accelerate discovery into the links between sleep and daytime function. Poor sleep has reached epidemic proportions in developed countries, negatively impacting nearly every aspect of our daily lives. Shockingly, after decades of research, the mechanisms by which insufficient or disturbed sleep impacts behavioral and social functioning remain poorly understood.
  •  
  • Mandibular Advancement Pharmacologic Augmentation Trial (MAP)
    Sponsored by the Chancellor’s Discovery Award
    IRB# 2012-0629
    PI: David W. Carley PhD, Bharati Prasad MD MS, Therese Galang
    This pilot study will test the benefit of augmenting standard mandibular advancement therapy for mild to moderate obstructive sleep apnea with a combination of ondansetron and fluoxetine. The goal is to improve the efficacy of the advancement devices.
     
  • Pharmacotherapy of Apnea by Cannabimimetic Enhancement (PACE)
    Sponsored by NHLBI
    IRB# 2012-0095
    PI: David W. Carley, PhD
    Co-Investigator: Bharati Prasad MD MS, Hui Xie PhD
    UIC is the lead site for this multi-site Phase II randomized controlled trial of dronabinol in obstructive sleep apnea. The study will determine the safety, tolerability and efficacy of cannabinoid therapy for sleep apnea. PACE is the largest trial of any drug treatment for sleep apnea to date, and the first multi-site RCT ever sponsored by the NIH.
     
    More information available on Clinicaltrials.gov
  •  
  • Targeted Treatment of Obstructive Sleep Apnea to Reduce Cardiovascular Disparity
    Sponsored by VA Clinical Science Research and Development Award
    IRB# 2013-1086
    Protocol# 1IK2CX001026-01
    PI: Bharati Prasad MD MS
    This study examines the cardiovascular effects of continuous positive airway pressure treatment in veterans with moderate to severe obstructive sleep apnea.
     
    More information available on Clinicaltrials.gov
 


Along with our clinical research, we have a very active basic science research program that explores the molecular and physiological causes of lung disease, allergy, and sleep disorders.


CURRENT STUDIES
 

 

  • Cholesterol regulation of K+ channels
    PI: Irena Levitan, PhD
    Elevation of plasma cholesterol is well-known to be a major risk factor in the development of Cardiovascular disease but the mechanisms by which cholesterol regulates the function of membrane proteins are still poorly understood. Our studies focus on inwardly rectifying K+ channels, a major type of K+ channels that are expressed in multiple cell types including endothelial cells, macrophages, smooth muscle cells, cardiomyocytes, and neurons and they play key roles in the regulation of electrical properties of the cellular membranes, cellular excitability and signaling.
     
    More information regarding this project available under Levitan’s Lab-Current Projects
     
  • Impact of Oxidized Lipids on Endothelial Biomechanics
    PI: Irena Levitan, PhD
    Multiple studies established that oxidized modifications of lipoproteins, such as oxLDL, are major risk factors for the development of atherosclerosis. However, the mechanisms of oxLDL-induced endothelial dysfunction are still poorly understood. Our studies discovered that oxLDL results in an increase in stiffness of aortic endothelial cells and we propose that endothelial stiffening is the key early step in endothelial dysfunction that leads to the disruption of the endothelial barrier and alters the sensitivity of endothelial cells to shear stress forces.
     
    More information regarding this project available under Levitan’s Lab-Current Projects
     
  • Intralipid: A novel frontline countermeasure for brodifacoum poisoning
    PI: Israel Rubinstein, MD
    Co-PI's: Douglas Feinstein, PhD, Guy Weinberg, MD
    To determine whether Intralipid, a FDA-approved fat emulsion for parenteral nutritional support, mitigates the deleterious effects of brodifacoum, a long-acting anticoagulant rodenticide (aka 'super-warfarin').
  •  
  • Mechanisms of Down Regulated Kv Channels: Role of microRNAs
    PI: Jason X.-J. Yuan, MD, PhD
    The overall goal in this study is to identify the Kv channels that are downregualted in PAH (Pulmonary Arterial Hypertension), resulting in increased PASMC (Pulmonary Arterial Smooth Muscle Cells) proliferation and decreasing PASMC apoptosis, increasing Pulmonary Vascular Ressitance. In addition to downregualted Kv channels, we hope to identify upregualted miRNAs that may regulate the stability and transcription of Kv channel mRNAs. The long-term goal of this study is to define the mechanism underlying the inhibition of Kv channels in IPAH-PASMC and to explore the possibility of targeting miRNA for developing therapeutic approaches for IPAH.
  •  
  • Neurobiology of Sleep Apnea in Aging
    PI: David W. Carley, PhD
    Previous funding cycles of this award have begun to define the brainstem networks responsible for the significant changes in cardiorespiratory function associated with transitions among various sleep/wake states. These changes are implicated in a variety of clinical disorders such as obstructive sleep apnea syndrome. In particular, this program has identified important respiratory modulating functions for the pedunculopontine tegmental (PPT) nucleus in the pons. The current funding cycle will define the role of orexin, a recently recognized neuromodulator, on PPT function and ultimately, on respiratory disturbances during sleep. This will help to clarify the mechanisms by which narcolepsy, a sleep disorder resulting from autoimmune loss of orexin in the brain, leads to both autonomic dysfunction and obstructive sleep apnea syndrome.
  •  
  • Regulation of Neutrophilic Lung Inflammation
    PI: Gye Young Park, MD MSc
    We propose to investigate the pre-transcriptional events in pulmonary macrophages that lead to cytokine- and chemokine-mediated inflammation in the lung. In previous years of funding, we have focused on the early effects of NADPH oxidase that result in attenuation of the NF-κB Activation pathway. We now propose to investigate the role of NADPH oxidase in the resolution of neutrophilic lung inflammation in pulmonary macrophages. By examining the physiological role of NADPH oxidase on the resolution of neutrophilc lung inflammation, we expect to identify novel mechanisms that could provide evidence for effective therapeutic approaches to limit lung injury and restore health in patients suffering from ARDS and other inflammation lung diseases.
     
    More inoformation regarding this project available under Park Current Research
  •  
  • Role of p67phox in myocardial hypertrophy
    PI: Lei Xiao, MD, PhD
    The overall goal of this project is to identify the novel signaling mechanisms of  NADPH oxidase (NOX) and its subunit p67phox in the development of cardiac hypertrophy. By generation of a transgenic mouse model with cardiac-specific inhibition of p67phox/NOX enzyme function, we are investigating the role of p67phox/NOX in regulation of cardiac growth and hypertrophy in response to multiple hypertrophic stimuli including chronic pressure-overload and alpha-1 adrenergic receptor stimulation in the heart.
 

FACULTY RESEARCH INTERESTS
 

 

 

 

Last Updated 11/12/2013